The Fore-Sight Elite is lighter and more portable than the earlier model, with a larger, higher contrast viewing screen and intuitive touch-screen controls.

Fore-Sight Elite uses five wavelengths of light to interrogate tissue under the sensor in order to measure oxygenation at greater levels of accuracy.

CASMed president and CEO Thomas M Patton noted with ELITE’s new features, lower production cost, and even greater accuracy, the company has widened its competitive advantage.

"We believe the ELITE can increase our share of the market and also drive overall market growth by helping establish cerebral oximetry as a standard of care," Patton added.

The system received the US Food and Drug Administration (FDA) approval in April 2013 and began a controlled product introduction with select customers for evaluation purposes.